VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.68%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$223M
AUM Growth
-$41.4M
(-16%)
Cap. Flow
-$33.4M
Cap. Flow
% of AUM
-14.95%
Top 10 Holdings %
Top 10 Hldgs %
11%
Holding
420
New
44
Increased
50
Reduced
231
Closed
47
Top Buys
| 1 |
The Mosaic Company
MOS
|
$2.75M |
| 2 |
STR
Sitio Royalties
STR
|
$2.32M |
| 3 |
Copel
ELP
|
$2.31M |
| 4 |
Vale
VALE
|
$2.26M |
| 5 |
Nutrien
NTR
|
$2.24M |
Top Sells
| 1 |
Boise Cascade
BCC
|
$2.62M |
| 2 |
Extra Space Storage
EXR
|
$2.49M |
| 3 |
Canadian Natural Resources
CNQ
|
$2.46M |
| 4 |
Imperial Oil
IMO
|
$2.45M |
| 5 |
Avient
AVNT
|
$2.42M |
Sector Composition
| 1 | Materials | 20.16% |
| 2 | Real Estate | 20.02% |
| 3 | Healthcare | 16.51% |
| 4 | Energy | 10.55% |
| 5 | Utilities | 10.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Caribou Biosciences
CRBU
$172M
| $86K | 0.04% |
9,392
-557
| -6% | -$5.1K |
|
|
KRON
327
DELISTED
Kronos Bio
KRON
| $86K | 0.04% |
11,844
-704
| -6% | -$5.11K |
|
328
Alaunos Therapeutics
TCRT
$4.27M
| $86K | 0.04% |
876
-52
| -6% | -$5.11K |
|
329
Quince Therapeutics
QNCX
$86.2M
| $85K | 0.04% |
13,657
-814
| -6% | -$5.07K |
|
|
CMPS
330
Compass Pathways
CMPS
$489M
| $84K | 0.04% |
6,524
-389
| -6% | -$5.01K |
|
331
MacroGenics
MGNX
$123M
| $84K | 0.04% |
9,556
-564
| -6% | -$4.96K |
|
332
Nuvation Bio
NUVB
$1.17B
| $84K | 0.04% |
16,034
-952
| -6% | -$4.99K |
|
333
Curis
CRIS
$21.4M
| $83K | 0.04% |
1,742
-104
| -6% | -$4.96K |
|
334
Lexicon Pharmaceuticals
LXRX
$389M
| $82K | 0.04% |
39,262
-2,322
| -6% | -$4.85K |
|
335
ESSA Pharma
EPIX
$11M
| $80K | 0.04% |
12,885
-758
| -6% | -$4.71K |
|
336
IDEAYA Biosciences
IDYA
$2.26B
| $80K | 0.04% |
7,192
-430
| -6% | -$4.78K |
|
337
Nurix Therapeutics
NRIX
$697M
| $80K | 0.04% |
5,676
-334
| -6% | -$4.71K |
|
338
Scholar Rock
SRRK
$3.12B
| $80K | 0.04% |
6,212
-366
| -6% | -$4.71K |
|
339
ATAI Life Sciences
ATAI
$977M
| $79K | 0.04% |
15,469
-924
| -6% | -$4.72K |
|
340
CureVac
CVAC
$1.2B
| $79K | 0.04% |
4,028
-230
| -5% | -$4.51K |
|
341
Edgewise Therapeutics
EWTX
$1.54B
| $79K | 0.04% |
8,129
-475
| -6% | -$4.62K |
|
342
Shattuck Labs
STTK
$72.3M
| $79K | 0.04% |
18,546
-1,102
| -6% | -$4.69K |
|
343
CEL-SCI Corp
CVM
$77.4M
| $77K | 0.03% |
654
-39
| -6% | -$4.59K |
|
344
Vor Biopharma
VOR
$244M
| $76K | 0.03% |
12,572
-739
| -6% | -$4.47K |
|
|
LENZ
345
LENZ Therapeutics
LENZ
$1.14B
| $76K | 0.03% |
2,138
-127
| -6% | -$4.51K |
|
346
Olema Pharmaceuticals
OLMA
$436M
| $73K | 0.03% |
17,135
-1,015
| -6% | -$4.32K |
|
347
Passage Bio
PASG
$22.3M
| $72K | 0.03% |
1,166
-69
| -6% | -$4.26K |
|
348
Pliant Therapeutics
PLRX
$100M
| $72K | 0.03% |
10,224
-603
| -6% | -$4.25K |
|
349
Taysha Gene Therapies
TSHA
$889M
| $71K | 0.03% |
10,878
-641
| -6% | -$4.18K |
|
|
KLRS
350
Kalaris Therapeutics, Inc. Common Stock
KLRS
$87.2M
| $71K | 0.03% |
455
-27
| -6% | -$4.21K |
|